论文部分内容阅读
2015年6月,吡唑醚菌酯中国专利到期,这使得不少国内企业蠢蠢欲动,在专利到期前,便开始进行相应的技术储备和市场调研。目前国内该产品登记已成热点,不仅专利拥有者德国巴斯夫公司大力扩展其复配制剂,国内企业也如火如荼,纷纷推出其单剂或复配制剂。而在专利到期之前,巴斯夫一直高度关注其专利保护,对侵犯巴斯夫吡唑醚菌酯专利权的任何单位和个人,表示会采取一切法律手段追究其民事、行政和刑事责任。面对一个全球上亿美元
In June 2015, the Chinese patent for pyraclostrobin expired, which made many domestic enterprises ready to make the corresponding technical reserve and market research before the patent expired. At present, the product registration has become a hot spot in China. Not only the patent holder, BASF in Germany, has vigorously expanded its compounding preparations. Domestic enterprises are also in full swing and have launched their single-dose or multi-agent preparations. Prior to the expiration of the patent, BASF has always been paying close attention to the protection of its patents. Any unit or individual that infringes the patent on pyrazole ether of BASF said it will take all legal measures to pursue its civil, administrative and criminal responsibilities. Face a global billions of dollars